

May 13, 2023

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

**Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) by Glenmark Pharmaceuticals Limited (GPL) in respect of Incorporation of a wholly owned subsidiary company**

Pursuant to the provisions of Regulation 30 of SEBI Listing Regulations, we wish to inform you that a wholly-owned subsidiary company of GPL in the name of “Glenmark Healthcare Limited” has been incorporated on May 12, 2023 under corporate identity number U21001MH2023PLC402796 (“WOS”).

The details/disclosures in respect of the said WOS, as required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided in the enclosed **Annexure**.

We request you to take the above on record and consider the same as compliance under the applicable provisions of the SEBI Listing Regulations.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**Annexure**

Required disclosures/details in respect of Incorporation of a wholly-owned subsidiary company by Glenmark Pharmaceuticals Limited (GPL), pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1	Name of the incorporated entity, details in brief such as size, turnover, etc.	Glenmark Healthcare Limited (WOS)  Authorized capital: Rs. 5,00,000/- (Rupees Five Lakhs only). Subscribed capital: Rs. 5,00,000/- (Rupees Five Lakhs only).  WOS is newly incorporated entity and presently, has no turnover.
2	Whether the WOS would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	N.A.  WOS is newly incorporated entity.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	Manufacturing and trading of Pharmaceutical products.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition.	WOS has already been formed and the capital is held by GPL with effect from May 12, 2023.

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

7	Nature of consideration - whether cash consideration or share swap and details of the same.	100% in Cash
8	Cost of acquisition or the price at which the shares are acquired.	At par- ₹ 500,000
9	Percentage of shareholding /control acquired and/ or number of shares acquired.	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Glenmark Healthcare Limited (WOS), is a public limited company incorporated on May 12, 2023 under the provisions of the Companies Act, 2013, under the CIN-U21001MH2023PLC402796, having its registered office in the Mumbai, State of Maharashtra, India. Its main object <i>inter-alia</i> is to carry out manufacturing and trading of Pharmaceutical products.

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)